Phenotypes associated with this allele

• Allele Symbol: Tg(Col1a1-cre)1Kry
• Allele Name: transgene insertion 1, Gerard Karsenty
• Allele ID: MGI:3041864
• Summary: 55 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Prkar1a^tm1.2Lsk/Prkar1a^+ Rb1^tm2Brn/Rb1^+ Tg(Col1a1-cre)1Kry/0 Trp53^tm1Brn/Trp53^tm1Brn	involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5796166
cn2	Prkar1a^tm1.2Lsk/Prkar1a^+ Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Col1a1-cre)1Kry/0	involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5796167
cn3	Dlg2^tm1a(EUCOMM)Wtsi/Dlg2^tm1a(EUCOMM)Wtsi Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Col1a1-cre)1Kry/0	involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N	MGI:7484008
cn4	Rb1^tm2Brn/Rb1^tm2Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Col1a1-cre)1Kry/0	involves: 129 * 129P2/OlaHsd * FVB/N	MGI:5796161
cn5	Rb1^tm2Brn/Rb1^+ Trp53^tm1Brn/Trp53^tm1Brn Tg(Col1a1-cre)1Kry/0	involves: 129 * 129P2/OlaHsd * FVB/N	MGI:5796164
cn6	Hdac8^tm1.1Eno/Y Tg(Col1a1-cre)1Kry/0	involves: 129 * C57BL/6 * CD-1 * FVB/N	MGI:3851915
cn7	Adipor2^tm1.1Kry/Adipor2^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129 * C57BL/6J * FVB	MGI:5520071
cn8	Adipor1^tm1.1Kry/Adipor1^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129 * C57BL/6J * FVB	MGI:5520070
cn9	Cdh13^tm1.1Kry/Cdh13^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129 * C57BL/6J * FVB	MGI:5520073
cn10	Ptpn2^tm1.1Kry/Ptpn2^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129 * C57BL/6J * FVB	MGI:5319229
cn11	Ptpn1^tm1.1Kry/Ptpn1^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129 * C57BL/6J * FVB	MGI:5319230
cn12	Adipor1^tm1.1Kry/Adipor1^tm1.1Kry Adipor2^tm1.1Kry/Adipor2^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129 * C57BL/6J * FVB	MGI:5520072
cn13	Creb1^tm3Gsc/Creb1^+ Lrp5^tm1Kry/Lrp5^+ Tg(Col1a1-cre)1Kry/0	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB	MGI:3837412
cn14	Prkar1a^tm1.2Lsk/Prkar1a^+ Tg(Col1a1-cre)1Kry/0 Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5796169
cn15	Creb1^tm3Gsc/Creb1^+ Htr1b^tm1Rhn/Htr1b^tm1Rhn Tg(Col1a1-cre)1Kry/0	involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N	MGI:3837414
cn16	Gt(ROSA)26Sor^tm1(Notch1)Dam/Gt(ROSA)26Sor^+ Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Col1a1-cre)1Kry/0	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N	MGI:5883005
cn17	Rbpj^tm1Hon/Rbpj^tm1Hon Tg(Col1a1-cre)1Kry/0	involves: 129P2/OlaHsd * C57BL/6 * FVB/N	MGI:5882984
cn18	Tg(Bglap2-TAg)1Rkho/0 Tg(Col1a1-cre)1Kry/0 Tnfrsf11a^tm1.1Pngr/Tnfrsf11a^tm1.1Pngr	involves: 129P2/OlaHsd * C57BL/6 * FVB/N	MGI:5796173
cn19	Atf4^tm1Kry/Atf4^tm1Kry Creb1^tm3Gsc/Creb1^tm3Gsc Tg(Col1a1-cre)1Kry/0	involves: 129P2/OlaHsd * C57BL/6J * FVB	MGI:4360509
cn20	Stat3^tm1Aki/Stat3^tm2Aki Tg(Col1a1-cre)1Kry/0	involves: 129P2/OlaHsd * FVB/N * C57BL/6	MGI:3843780
cn21	Adipoq^tm1Ish/Adipoq^tm1Ish Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Tg(Col1a1-cre)1Kry/0	involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J * FVB/N	MGI:5520079
cn22	Ctnnb1^tm2Kem/Ctnnb1^tm2Kem Tg(Col1a1-cre)1Kry/0	involves: 129S1/Sv * 129X1/SvJ * FVB	MGI:5319653
cn23	Prkar1a^tm1.2Lsk/Prkar1a^+ Tg(Col1a1-cre)1Kry/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5796038
cn24	Prkar1a^tm1.2Lsk/Prkar1a^tm1.2Lsk Tg(Col1a1-cre)1Kry/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5796037
cn25	Prkar1a^tm1.2Lsk/Prkar1a^+ Tg(Bglap2-TAg)1Rkho/0 Tg(Col1a1-cre)1Kry/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5796026
cn26	Foxo1^tm1Rdp/Foxo1^tm1.1Rdp Tg(Col1a1-cre)1Kry/0	involves: 129S1/Sv * FVB	MGI:5520078
cn27	Mmp13^tm1Werb/Mmp13^tm1Werb Tg(Col1a1-cre)1Kry/0	involves: 129S2/SvPas	MGI:3522356
cn28	Fgfr3^tm2Llm/Fgfr3^+ Tg(Col1a1-cre)1Kry/0	involves: 129S2/SvPas * C57BL/6 * FVB	MGI:5426514
cn29	Esrra^tm1.1Ics/Esrra^tm1.1Ics Tg(Col1a1-cre)1Kry/0	involves: 129S2/SvPas * FVB	MGI:5496793
cn30	Mirc21^tm1.1Kry/Mirc21^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129S4/SvJaeSor * 129S6/SvEvTac * FVB/N	MGI:5427925
cn31	Mirc21^tm1.1Kry/Mirc21^tm1.1Kry Satb2^tm1Rug/Satb2^+ Tg(Col1a1-cre)1Kry/0	involves: 129S4/SvJaeSor * 129S6/SvEvTac * FVB/N	MGI:5427924
cn32	Mir34a^tm1.1Kry/Mir34a^tm1.1Kry Mirc21^tm1.1Kry/Mirc21^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129S4/SvJaeSor * 129S6/SvEvTac * FVB/N	MGI:5427926
cn33	Gt(ROSA)26Sor^tm1(Notch1)Dam/Gt(ROSA)26Sor^+ Tg(Col1a1-cre)1Kry/0	involves: 129S4/SvJaeSor * C57BL/6 * FVB/N	MGI:5882988
cn34	Ccnf^tm1Sje/Ccnf^tm1.1Sje Tg(Col1a1-cre)1Kry/0	involves: 129S7/SvEvBrd * C57BL/6 * FVB	MGI:3041866
cn35	Adipoq^tm1Ish/Adipoq^tm1Ish Adrb2^tm1Kry/Adrb2^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: 129S7/SvEvBrd * C57BL/6J * FVB	MGI:5520076
cn36	Bglap/Bglap2^tm1Kry/Bglap^+ Ptprv^tm1Kry/Ptprv^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: 129S7/SvEvBrd * FVB	MGI:3763094
cn37	Per1^tm1Brd/Per1^tm1Brd Per2^tm1Brd/Per2^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: 129S7/SvEvBrd * FVB	MGI:4362037
cn38	Bglap/Bglap2^tm1Kry/Bglap2^+ Ptprv^tm1Kry/Ptprv^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: 129S7/SvEvBrd * FVB	MGI:3763095
cn39	Ctnnb1^tm1Mmt/Ctnnb1^+ Tg(Col1a1-cre)1Kry/0	involves: 129X1/SvJ * FVB	MGI:5319652
cn40	Smad1^tm1Abr/Smad1^tm1.1Abr Tg(Col1a1-cre)1Kry/0	involves: BALB/cJ * C57 * FVB	MGI:5009240
cn41	Adrb2^tm1Kry/Adrb2^+ Lep^ob/Lep^+ Tg(Col1a1-cre)1Kry/0	involves: C57BL/6 * C57BL/10J * FVB	MGI:3837367
cn42	Tg(Col1a1-cre)1Kry/0 Vdr^tm2Ska/Vdr^tm2Ska	involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj * FVB/N	MGI:5501520
cn43	Atf4^tm1Kry/Atf4^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: C57BL/6J * FVB	MGI:4360510
cn44	Runx2^tm1.1Yyon/Runx2^tm1.1Yyon Tg(Col1a1-cre)1Kry/0	involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/N	MGI:5570666
cn45	Tph1^tm1Kry/Tph1^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:3837408
cn46	Lrp5^tm3(Lrp5*)Kry/Lrp5^tm3(Lrp5*)Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:3837406
cn47	Lrp5^tm2Kry/Lrp5^tm2Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:3837402
cn48	Adrb2^tm1Kry/Adrb2^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:3837366
cn49	Ptprv^tm1Kry/Ptprv^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:3763086
cn50	Htr2b^tm1Kry/Htr2b^tm1Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:3837410
cn51	Bglap/Bglap2^tm3.1Kry/Bglap/Bglap2^tm3.1Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:4949144
cn52	Bglap/Bglap2^tm3.1Kry/Bglap/Bglap2^tm3.1Kry Tg(Col1a1-cre)1Kry/0	involves: FVB	MGI:4949147
cn53	Runx2^tm1Mjo/Runx2^+ Runx3^tm3Yg/Runx3^tm3Yg Tg(Col1a1-cre)1Kry/0	involves: FVB/N	MGI:5689562
cn54	Runx3^tm3Yg/Runx3^tm3Yg Tg(Col1a1-cre)1Kry/0	involves: FVB/N	MGI:5689556
cn55	Ggcx^tm1.1Kry/Ggcx^tm1.1Kry Tg(Col1a1-cre)1Kry/0	involves: FVB/N	MGI:6198735

Genotype
MGI:5796166

cn1

• Allelic Composition: Prkar1a^tm1.2Lsk/Prkar1a⁺; Rb1^tm2Brn/Rb1⁺; Tg(Col1a1-cre)1Kry/0; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:234128 )

• mice survive to around 13.9 weeks

• treatment of mice with RANK-Fc prolongs survival to around 17.8 weeks

neoplasm

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma within 10.3 weeks of age

• tumors are marked by high TNFSF11 (RANKL)/low TNFRSF11A (RANK) levels

• treatment of mice with RANK-Fc for 52 weeks beginning at 12.6 weeks of age keeps mice tumor-free until 64.6 weeks of age

skeleton

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma within 10.3 weeks of age

• tumors are marked by high TNFSF11 (RANKL)/low TNFRSF11A (RANK) levels

• treatment of mice with RANK-Fc for 52 weeks beginning at 12.6 weeks of age keeps mice tumor-free until 64.6 weeks of age

cellular

increased cell migration ( J:234128 )

• in a scratch wound healing assay, tumor cells show greater migration than tumor cells from conditional Rb1^tm2Brn heterozygous Trp53^tm1Brn homozygous double mutants

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
osteosarcoma		DOID:3347	OMIM:259500	J:234128

Genotype
MGI:5796167

cn2

• Allelic Composition: Prkar1a^tm1.2Lsk/Prkar1a⁺; Rb1^tm2Brn/Rb1^tm2Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:234128 )

• mice do not live longer than 11 weeks

• treatment of mice with RANK-Fc prolongs survival to around to around 13.3 weeks

neoplasm

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma within 6.3 weeks of age

• tumors are marked by high (TNFSF11) RANKL/low (TNFRSF11A) RANK levels

• treatment of mice with RANK-Fc starting at 2.4 weeks of age suppresses tumor growth

• mice develop tumors 4.3 weeks after the discontinuation of RANK-Fc treatment and large numbers of osteoclasts are seen lining the boundary of tumor cells and adjacent osteopetrotic bone

skeleton

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma within 6.3 weeks of age

• tumors are marked by high (TNFSF11) RANKL/low (TNFRSF11A) RANK levels

• treatment of mice with RANK-Fc starting at 2.4 weeks of age suppresses tumor growth

• mice develop tumors 4.3 weeks after the discontinuation of RANK-Fc treatment and large numbers of osteoclasts are seen lining the boundary of tumor cells and adjacent osteopetrotic bone

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
osteosarcoma		DOID:3347	OMIM:259500	J:234128

Genotype
MGI:7484008

cn3

• Allelic Composition: Dlg2^{tm1a(EUCOMM)Wtsi}/Dlg2^{tm1a(EUCOMM)Wtsi}; Rb1^tm2Brn/Rb1^tm2Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N
• Cell Lines: EPD0635_5_E12

mortality/aging

premature death ( J:269943 )

• mice exhibit a shortened overall survival, with a median lifespan of 184 days versus 239 days in control littermates that are wild-type for Dlg2

neoplasm

increased tumor growth/size ( J:269943 )

• tumor cells are more proliferative than those in control littermates that are wild-type for Dlg2, as indicated by Ki-67 staining

increased osteosarcoma incidence ( J:269943 )

• mice show accelerated osteosarcoma development with anatomical distribution and histological features similar to those in control littermates that are wild-type for Dlg2

• osteoblastic tumors are aggressive in nature, as indicated by abundant osteoid deposition at the invasive front of thoracic vertebra osteosarcomas

• plump tumorous osteoblasts and massive osteoid deposition are seen in tumors that develop at different sites

decreased tumor latency ( J:269943 )

• at 22 weeks of age, mice show accelerated tumor onset with visible signs of osteosarcomas on the tibia and ribs, unlike control littermates that are wild-type for Dlg2

skeleton

increased osteosarcoma incidence ( J:269943 )

• mice show accelerated osteosarcoma development with anatomical distribution and histological features similar to those in control littermates that are wild-type for Dlg2

• osteoblastic tumors are aggressive in nature, as indicated by abundant osteoid deposition at the invasive front of thoracic vertebra osteosarcomas

• plump tumorous osteoblasts and massive osteoid deposition are seen in tumors that develop at different sites

Genotype
MGI:5796161

cn4

• Allelic Composition: Rb1^tm2Brn/Rb1^tm2Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * 129P2/OlaHsd * FVB/N

mortality/aging

premature death ( J:234128 )

• mice survive up to 38.1 weeks of age

neoplasm

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma by 20 weeks of age

skeleton

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma by 20 weeks of age

Genotype
MGI:5796164

cn5

• Allelic Composition: Rb1^tm2Brn/Rb1⁺; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * 129P2/OlaHsd * FVB/N

mortality/aging

premature death ( J:234128 )

• mice survive up to 55.4 weeks of age

neoplasm

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma by 35 weeks of age

• tumors are marked by low TNFSF11 (RANKL)/high TNFRSF11A (RANK) levels

skeleton

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma by 35 weeks of age

• tumors are marked by low TNFSF11 (RANKL)/high TNFRSF11A (RANK) levels

Genotype
MGI:3851915

cn6

• Allelic Composition: Hdac8^tm1.1Eno/Y; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * C57BL/6 * CD-1 * FVB/N

normal phenotype

no abnormal phenotype detected ( J:150709 )

♂ • no abnormal phenotype is detected in skull development

Genotype
MGI:5520071

cn7

• Allelic Composition: Adipor2^tm1.1Kry/Adipor2^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:199264 )

N • mice exhibit normal osteocalcin serum levels

skeleton

skeleton phenotype ( J:199264 )

N • mice exhibit normal bone mass and osteoblast

Genotype
MGI:5520070

cn8

• Allelic Composition: Adipor1^tm1.1Kry/Adipor1^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:199264 )

N • mice exhibit normal osteocalcin serum levels

skeleton

skeleton phenotype ( J:199264 )

N • mice exhibit normal bone mass and osteoblast

Genotype
MGI:5520073

cn9

• Allelic Composition: Cdh13^tm1.1Kry/Cdh13^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:199264 )

N • mice exhibit normal osteocalcin serum levels

skeleton

skeleton phenotype ( J:199264 )

N • mice exhibit normal bone mass and osteoblast

Genotype
MGI:5319229

cn10

• Allelic Composition: Ptpn2^tm1.1Kry/Ptpn2^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:183709 )

N • mice fed standard chow or a high fat diet exhibit normal glucose tolerance

increased circulating osteocalcin level ( J:183709 )

• mice exhibit increased serum level of undercarboxylated (i.e. active) ostecalcin compared with wild-type mice

increased energy expenditure ( J:183709 )

• during the day but not night

increased carbon dioxide production ( J:183709 )

• during the day but not night

increased oxygen consumption ( J:183709 )

• during the day but not night

increased insulin sensitivity ( J:183709 )

skeleton

skeleton phenotype ( J:183709 )

N • osteoblast differentiation and proliferation are normal

abnormal osteoclast differentiation ( J:183709 )

• osteoblasts co-cultured with wild-type monocyte in the presence of vitamin D3 and prostaglandin E2 exhibit increased osteoclast differentiation compared with wild-type osteoblasts

• however, osteoclast number in vivo is normal

abnormal osteoclast physiology ( J:183709 )

• increased activity

increased bone resorption ( J:183709 )

• due to increased osteoclast activity

immune system

abnormal osteoclast differentiation ( J:183709 )

• osteoblasts co-cultured with wild-type monocyte in the presence of vitamin D3 and prostaglandin E2 exhibit increased osteoclast differentiation compared with wild-type osteoblasts

• however, osteoclast number in vivo is normal

abnormal osteoclast physiology ( J:183709 )

• increased activity

cellular

abnormal osteoclast differentiation ( J:183709 )

• osteoblasts co-cultured with wild-type monocyte in the presence of vitamin D3 and prostaglandin E2 exhibit increased osteoclast differentiation compared with wild-type osteoblasts

• however, osteoclast number in vivo is normal

hematopoietic system

abnormal osteoclast differentiation ( J:183709 )

• osteoblasts co-cultured with wild-type monocyte in the presence of vitamin D3 and prostaglandin E2 exhibit increased osteoclast differentiation compared with wild-type osteoblasts

• however, osteoclast number in vivo is normal

abnormal osteoclast physiology ( J:183709 )

• increased activity

Genotype
MGI:5319230

cn11

• Allelic Composition: Ptpn1^tm1.1Kry/Ptpn1^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:183709 )

N • mice exhibit normal insulin sensitivity and glucose tolerance

Genotype
MGI:5520072

cn12

• Allelic Composition: Adipor1^tm1.1Kry/Adipor1^tm1.1Kry; Adipor2^tm1.1Kry/Adipor2^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129 * C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:199264 )

N • mice exhibit normal osteocalcin serum levels

skeleton

skeleton phenotype ( J:199264 )

N • mice exhibit normal bone mass and osteoblast

Genotype
MGI:3837412

cn13

• Allelic Composition: Creb1^tm3Gsc/Creb1⁺; Lrp5^tm1Kry/Lrp5⁺; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB

skeleton

decreased bone mass ( J:146078 )

• phenotype is indistinguishable from mice homozygous null for Lrp5

decreased bone ossification ( J:146078 )

• decreased bone formation

Genotype
MGI:5796169

cn14

• Allelic Composition: Prkar1a^tm1.2Lsk/Prkar1a⁺; Tg(Col1a1-cre)1Kry/0; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:234128 )

• mice survive to around 17 weeks of age

neoplasm

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma within 17 weeks of age

• multiple tumors among long bones, spine, jaw, and skull

• tumors are composed of malignant-appearing osteoblasts with woven bone as the predominant matrix and occasional chondroblastic or fibroblastic phenotype

• tumors are marked by high TNFSF11 (RANKL)/low TNFRSF11A (RANK) levels

skeleton

increased osteosarcoma incidence ( J:234128 )

• mice develop osteosarcoma within 17 weeks of age

• multiple tumors among long bones, spine, jaw, and skull

• tumors are composed of malignant-appearing osteoblasts with woven bone as the predominant matrix and occasional chondroblastic or fibroblastic phenotype

• tumors are marked by high TNFSF11 (RANKL)/low TNFRSF11A (RANK) levels

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
osteosarcoma		DOID:3347	OMIM:259500	J:234128

Genotype
MGI:3837414

cn15

• Allelic Composition: Creb1^tm3Gsc/Creb1⁺; Htr1b^tm1Rhn/Htr1b^tm1Rhn; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N

skeleton

skeleton phenotype ( J:146078 )

N • loss of expression of 1 copy of Creb1 in osteoblasts rescues the bone phenotype seen in Htrb1 null mice

Genotype
MGI:5883005

cn16

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Notch1)Dam}/Gt(ROSA)26Sor⁺; Rbpj^tm1Hon/Rbpj^tm1Hon; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N

skeleton

skeleton phenotype ( J:233131 )

N • mice exhibit rescue of growth retardation and osteosclerotic phenotypes seen in single Gt(ROSA)26Sor^{tm1(Notch1)Dam} conditional mice

Genotype
MGI:5882984

cn17

• Allelic Composition: Rbpj^tm1Hon/Rbpj^tm1Hon; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB/N

skeleton

skeleton phenotype ( J:233131 )

N • mice do not exhibit an abnormal bone phenotype at 2 months of age

Genotype
MGI:5796173

cn18

• Allelic Composition: Tg(Bglap2-TAg)1Rkho/0; Tg(Col1a1-cre)1Kry/0; Tnfrsf11a^tm1.1Pngr/Tnfrsf11a^tm1.1Pngr
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB/N

neoplasm

increased osteosarcoma incidence ( J:234128 )

• tumor onset, survival, tumor burden, and lung metastasis is comparable to single Tg(Bglap2-TAg)1Rkho hemizygous mice

skeleton

increased osteosarcoma incidence ( J:234128 )

• tumor onset, survival, tumor burden, and lung metastasis is comparable to single Tg(Bglap2-TAg)1Rkho hemizygous mice

Genotype
MGI:4360509

cn19

• Allelic Composition: Atf4^tm1Kry/Atf4^tm1Kry; Creb1^tm3Gsc/Creb1^tm3Gsc; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:152695 )

N • mice exhibit normal glucose and insulin homeostasis

Genotype
MGI:3843780

cn20

• Allelic Composition: Stat3^tm1Aki/Stat3^tm2Aki; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N * C57BL/6

skeleton

abnormal bone structure ( J:144906 )

• bone volume to tissue volume is reduced by half compared to controls

decreased trabecular bone thickness ( J:144906 )

• trabecular number and trabecular thickness are decreased in the tibia by about a third

• trabecular separation is increased by more than a third

abnormal bone ossification ( J:144906 )

• mineral apposition rate and bone formation rate are significantly reduced in these mice

Genotype
MGI:5520079

cn21

• Allelic Composition: Adipoq^tm1Ish/Adipoq^tm1Ish; Foxo1^tm1Rdp/Foxo1^tm1.1Rdp; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J * FVB/N

growth/size/body

growth/size/body region phenotype ( J:199264 )

N • mice exhibit normal body weight

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:199264 )

N • mice exhibit normal osteocalcin serum levels

skeleton

skeleton phenotype ( J:199264 )

N • mice exhibit normal bone mass and osteoblast numbers

Genotype
MGI:5319653

cn22

• Allelic Composition: Ctnnb1^tm2Kem/Ctnnb1^tm2Kem; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB

skeleton

increased osteoclast cell number ( J:98430 )

decreased bone mass ( J:98430 )

• at 1 month of age

hematopoietic system

increased osteoclast cell number ( J:98430 )

immune system

increased osteoclast cell number ( J:98430 )

Genotype
MGI:5796038

cn23

• Allelic Composition: Prkar1a^tm1.2Lsk/Prkar1a⁺; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

Bone tumorigenesis nd abundant osteoclasts in Prkar1a^tm1.2Lsk/Prkar1a⁺ Tg(Col1a1-cre)1Kry/0 mice

neoplasm

increased skeletal tumor incidence ( J:165282 )

• mice develop bone tumors starting at 10 weeks of age, with most mice having tumors by 40 weeks of age

• lesions grow slowly, with 25% of mice having 8-mm tumors by 50 weeks of age

• mice do not develop metastases

• lesions are not typical osteosarcomas as they are not composed of malignant osteoblasts depositing osteoid, but consist of an enlarged marrow space filled with abundant myxoid matrix, containing small fibroblast-like cells surrounded by trabecular-like bone, lined by normal osteoblasts and regions with abundant osteoclasts

skeleton

increased skeletal tumor incidence ( J:165282 )

• mice develop bone tumors starting at 10 weeks of age, with most mice having tumors by 40 weeks of age

• lesions grow slowly, with 25% of mice having 8-mm tumors by 50 weeks of age

• mice do not develop metastases

• lesions are not typical osteosarcomas as they are not composed of malignant osteoblasts depositing osteoid, but consist of an enlarged marrow space filled with abundant myxoid matrix, containing small fibroblast-like cells surrounded by trabecular-like bone, lined by normal osteoblasts and regions with abundant osteoclasts

abnormal bone remodeling ( J:165282 )

• bone within and around lesions is normal and contains osteocytes but is undergoing extensive remodeling

Genotype
MGI:5796037

cn24

• Allelic Composition: Prkar1a^tm1.2Lsk/Prkar1a^tm1.2Lsk; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

mortality/aging

neonatal lethality, complete penetrance ( J:165282 )

• mice die within 24 hours of birth

Genotype
MGI:5796026

cn25

• Allelic Composition: Prkar1a^tm1.2Lsk/Prkar1a⁺; Tg(Bglap2-TAg)1Rkho/0; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

Prkar1a heterozygosity accelerates osteosarcoma development in Tg(Bglap2-TAg)1Rkho/0 mice

mortality/aging

premature death ( J:165282 )

• no mice survive past 5 weeks of age

neoplasm

increased osteosarcoma incidence ( J:165282 )

• mice develop advanced osteosarcoma, often in the spine

• mice exhibit multi-ostotic tumors in long and flat bones, including the skull, vertebrae, ribs, and tibia

• however, metastasis is not seen at this early age

• tumors show increased osteoclast numbers

skeleton

increased osteosarcoma incidence ( J:165282 )

• mice develop advanced osteosarcoma, often in the spine

• mice exhibit multi-ostotic tumors in long and flat bones, including the skull, vertebrae, ribs, and tibia

• however, metastasis is not seen at this early age

• tumors show increased osteoclast numbers

behavior/neurological

abnormal motor capabilities/coordination/movement ( J:165282 )

• impaired mobility due to osteosarcoma in the spine

paralysis ( J:165282 )

• paralysis due to osteosarcoma in the spine

Genotype
MGI:5520078

cn26

• Allelic Composition: Foxo1^tm1Rdp/Foxo1^tm1.1Rdp; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S1/Sv * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:199264 )

N • mice exhibit normal osteocalcin serum levels

Genotype
MGI:3522356

cn27

• Allelic Composition: Mmp13^tm1Werb/Mmp13^tm1Werb; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S2/SvPas

skeleton

abnormal trabecular bone morphology ( J:94460 )

• the volume of trabecular bone is increased however the size of the hypertrophic chondrocyte zone is normal

Genotype
MGI:5426514

cn28

• Allelic Composition: Fgfr3^tm2Llm/Fgfr3⁺; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S2/SvPas * C57BL/6 * FVB

skeleton

skeleton phenotype ( J:183772 )

N • no obvious skeletal phenotype

N • normal growth plates

N • primary spongiosa is normal

N • normal trabecular bone

Genotype
MGI:5496793

cn29

• Allelic Composition: Esrra^tm1.1Ics/Esrra^tm1.1Ics; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S2/SvPas * FVB

skeleton

abnormal trabecular bone morphology ( J:195925 )

♀ • ovariectomized female mice do not exhibit loss of bone volume, bone mineral density or trabecular thickness unlike control mice

♀ • however, orchidectomized male mice exhibit normal loss of bone volume and bone mineral density

abnormal skeleton physiology ( J:195925 )

♀ • ovariectomized female mice are protected from bone loss compared with control mice

♀ • however, age-induced bone loss is normal

Genotype
MGI:5427925

cn30

• Allelic Composition: Mirc21^tm1.1Kry/Mirc21^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S4/SvJaeSor * 129S6/SvEvTac * FVB/N

Increased bone mass in Mirc21^tm1.1Kry/Mirc21^tm1.1Kry Tg(Col1a1-cre)1Kry/0 mice

skeleton

skeleton phenotype ( J:185130 )

N • osteoclast surface is normal

N • mice exhibit normal growth plate development

increased osteoblast proliferation ( J:185130 )

• increased osteoblast proliferation compared with controls

• however, osteoblast apoptosis is normal

increased bone mineral density ( J:185130 )

increased compact bone volume ( J:185130 )

increased compact bone thickness ( J:185130 )

increased osteoblast cell number ( J:185130 )

increased bone mass ( J:185130 )

• at 3 months

abnormal skeleton development ( J:185130 )

• increased bone formation rate compared with controls

enhanced osteoblast differentiation ( J:185130 )

• during embryonic development

abnormal bone mineralization ( J:185130 )

• premature

cellular

enhanced osteoblast differentiation ( J:185130 )

• during embryonic development

increased osteoblast proliferation ( J:185130 )

• increased osteoblast proliferation compared with controls

• however, osteoblast apoptosis is normal

Genotype
MGI:5427924

cn31

• Allelic Composition: Mirc21^tm1.1Kry/Mirc21^tm1.1Kry; Satb2^tm1Rug/Satb2⁺; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S4/SvJaeSor * 129S6/SvEvTac * FVB/N

skeleton

skeleton phenotype ( J:185130 )

N • mice exhibit normal bone mass, bone formation rate and osteoblast numbers

Genotype
MGI:5427926

cn32

• Allelic Composition: Mir34a^tm1.1Kry/Mir34a^tm1.1Kry; Mirc21^tm1.1Kry/Mirc21^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S4/SvJaeSor * 129S6/SvEvTac * FVB/N

Increased bone mass in Mir34a^tm1.1Kry/Mir34a^tm1.1Kry Mirc21^tm1.1Kry/Mirc21^tm1.1Kry Tg(Col1a1-cre)1Kry/0 mice

skeleton

skeleton phenotype ( J:185130 )

N • osteoclast surface is normal

increased osteoblast cell number ( J:185130 )

increased bone mass ( J:185130 )

• at 3 months

abnormal skeleton development ( J:185130 )

• increased bone formation rate

Genotype
MGI:5882988

cn33

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Notch1)Dam}/Gt(ROSA)26Sor⁺; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S4/SvJaeSor * C57BL/6 * FVB/N

growth/size/body

decreased body weight ( J:233131 )

• smaller body weight at P24

postnatal growth retardation ( J:233131 )

• from 2 weeks of age, mice show progressive growth retardation

skeleton

abnormal skeleton morphology ( J:233131 )

• thickened bones at 4 weeks of age

• cortices of bones are composed on woven bone in 2 month old mice

thick neurocranium ( J:233131 )

• increase in thickness of calvarial bone

abnormal bone marrow cavity morphology ( J:233131 )

• marrow space is enclosed by fibrotic cells with features of early osteoblastic precursors

abnormal trabecular bone morphology ( J:233131 )

• trabecular bone is composed predominately of immature woven rather than lamellar bone

• trabecular bone architecture is altered in 2 month old mice

increased trabecular bone volume ( J:233131 )

• trabecular bone volume/tissue volume is increased by more than 6-fold in 2 month old mice

increased bone trabecula number ( J:233131 )

• increase in trabecular number in 2 month old mice

decreased bone trabecular spacing ( J:233131 )

• decrease in trabecular spaces in 2 month old mice

increased trabecular bone thickness ( J:233131 )

• increase in trabecular bone thickness in 2 month old mice

increased bone mass ( J:233131 )

• increase in bone mass due to increased bone formation

osteosclerosis ( J:233131 )

• generalized osteosclerotic phenotype in skulls, rib cages, tail vertebrae, and limb long bones

limbs/digits/tail

kinked tail ( J:233131 )

• from 2 weeks of age, mice show a kinky tail

craniofacial

thick neurocranium ( J:233131 )

• increase in thickness of calvarial bone

Genotype
MGI:3041866

cn34

• Allelic Composition: Ccnf^tm1Sje/Ccnf^tm1.1Sje; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * FVB

skeleton

skeleton phenotype ( J:89060 )

N • no developmental or physiological defects are detected in bone

Genotype
MGI:5520076

cn35

• Allelic Composition: Adipoq^tm1Ish/Adipoq^tm1Ish; Adrb2^tm1Kry/Adrb2^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6J * FVB

skeleton

increased bone mass ( J:199264 )

• compared with wild-type mice and Adipoq^tm1Ish homozygotes

Genotype
MGI:3763094

cn36

• Allelic Composition: Bglap/Bglap2^tm1Kry/Bglap⁺; Ptprv^tm1Kry/Ptprv^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S7/SvEvBrd * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:126780 )

N • unlike in Ptprv^tm1Kry/ Ptprv^tm1Kry Tg(Col1a1-cre)1Kry mice, glucose homeostasis is normal

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:126780 )

N • unlike in Ptprv^tm1Kry/ Ptprv^tm1Kry Tg(Col1a1-cre)1Kry mice, beta-cell proliferation is normal

Genotype
MGI:4362037

cn37

• Allelic Composition: Per1^tm1Brd/Per1^tm1Brd; Per2^tm1Brd/Per2^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S7/SvEvBrd * FVB

skeleton

increased osteoblast cell number ( J:115188 )

increased bone mass ( J:115188 )

abnormal skeleton development ( J:115188 )

• increase in all bone formation parameters

Genotype
MGI:3763095

cn38

• Allelic Composition: Bglap/Bglap2^tm1Kry/Bglap2⁺; Ptprv^tm1Kry/Ptprv^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129S7/SvEvBrd * FVB

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:126780 )

N • unlike in Ptprv^tm1Kry/ Ptprv^tm1Kry Tg(Col1a1-cre)1Kry mice, beta-cell proliferation is normal

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:126780 )

N • unlike in Ptprv^tm1Kry/ Ptprv^tm1Kry Tg(Col1a1-cre)1Kry mice, glucose homeostasis is normal

Genotype
MGI:5319652

cn39

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: 129X1/SvJ * FVB

mortality/aging

lethality at weaning, complete penetrance ( J:98430 )

• normal for the first two weeks after birth but die within a few days after weaning

craniofacial

absent lower incisors ( J:98430 )

• form but fail to erupt

skeleton

absent lower incisors ( J:98430 )

• form but fail to erupt

decreased osteoclast cell number ( J:98430 )

increased osteoma incidence ( J:98430 )

• benign tumors in the ribs of 80% of mice

increased bone mass ( J:98430 )

neoplasm

increased osteoma incidence ( J:98430 )

• benign tumors in the ribs of 80% of mice

hematopoietic system

decreased osteoclast cell number ( J:98430 )

immune system

decreased osteoclast cell number ( J:98430 )

growth/size/body

absent lower incisors ( J:98430 )

• form but fail to erupt

Genotype
MGI:5009240

cn40

• Allelic Composition: Smad1^tm1Abr/Smad1^tm1.1Abr; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: BALB/cJ * C57 * FVB

skeleton

decreased osteoblast proliferation ( J:172689 )

• osteoblast proliferation is reduced compared to in wild-type mice

decreased osteoblast cell number ( J:172689 )

abnormal trabecular bone morphology ( J:172689 )

• mice exhibit increased trabecular separation and structural model index compared with wild-type mice

decreased trabecular bone volume ( J:172689 )

• at 2 months

decreased bone trabecula number ( J:172689 )

increased bone trabecular spacing ( J:172689 )

decreased trabecular bone connectivity density ( J:172689 )

decreased trabecular bone thickness ( J:172689 )

abnormal skeleton development ( J:172689 )

• bone formation rate is reduced compared to in wild-type mice

impaired osteoblast differentiation ( J:172689 )

• osteoblast differentiation is impaired compared to in wild-type mice

cellular

impaired osteoblast differentiation ( J:172689 )

• osteoblast differentiation is impaired compared to in wild-type mice

decreased osteoblast proliferation ( J:172689 )

• osteoblast proliferation is reduced compared to in wild-type mice

Genotype
MGI:3837367

cn41

• Allelic Composition: Adrb2^tm1Kry/Adrb2⁺; Lep^ob/Lep⁺; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: C57BL/6 * C57BL/10J * FVB

homeostasis/metabolism

decreased circulating glucose level ( J:145998 )

• mice exhibit postprandial low blood glucose levels compared to in wild-type mice

increased circulating insulin level ( J:145998 )

Genotype
MGI:5501520

cn42

• Allelic Composition: Tg(Col1a1-cre)1Kry/0; Vdr^tm2Ska/Vdr^tm2Ska
• Genetic Background: involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj * FVB/N

skeleton

skeleton phenotype ( J:196471 )

N • osteoblasts exhibit normal mineral metabolism

N • cortical thickness in the femur is normal at 16 weeks

abnormal osteoclast differentiation ( J:196471 )

• impaired

decreased osteoclast cell number ( J:196471 )

increased bone mineral density ( J:196471 )

• at 16 weeks

increased trabecular bone volume ( J:196471 )

• at 16 weeks

• however, trabecular bone volume of the distal femoral metaphysis at 4 and 9 weeks is normal

increased bone mass ( J:196471 )

• at 16 weeks

decreased bone resorption ( J:196471 )

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:196471 )

N • mice exhibit normocalcemia and normophosphatemia

cellular

abnormal osteoclast differentiation ( J:196471 )

• impaired

immune system

abnormal osteoclast differentiation ( J:196471 )

• impaired

decreased osteoclast cell number ( J:196471 )

hematopoietic system

abnormal osteoclast differentiation ( J:196471 )

• impaired

decreased osteoclast cell number ( J:196471 )

Genotype
MGI:4360510

cn43

• Allelic Composition: Atf4^tm1Kry/Atf4^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: C57BL/6J * FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:152695 )

N • serum leptin, resistin, and adiponectin levels are normal

abnormal glucose homeostasis ( J:152695 )

• insulin-stimulated whole-body glucose turnover is increased 40% compared to in similarly treated wild-type mice

increased insulin secretion ( J:152695 )

• following glucose challenge

decreased circulating glucose level ( J:152695 )

• at 2 weeks and 1 month

impaired gluconeogenesis ( J:152695 )

• reduced after pyruvate challenge

improved glucose tolerance ( J:152695 )

abnormal glycogen homeostasis ( J:152695 )

• insulin-stimulated whole-body glycogen synthesis is increased compared to in similarly treated wild-type mice

increased insulin sensitivity ( J:152695 )

endocrine/exocrine glands

increased insulin secretion ( J:152695 )

• following glucose challenge

growth/size/body

decreased body weight ( J:152695 )

Genotype
MGI:5570666

cn44

• Allelic Composition: Runx2^tm1.1Yyon/Runx2^tm1.1Yyon; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/N

mortality/aging

mortality/aging ( J:210124 )

N • mice are produced in normal Mendelian ratio

skeleton

skeleton phenotype ( J:210124 )

N • mice exhibit normal skeletal development

Genotype
MGI:3837408

cn45

• Allelic Composition: Tph1^tm1Kry/Tph1^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:146078 )

N • unlike mice with conditional deletion in the gut, mice with conditional expression in osteoblasts have normal circulating serotonin levels

skeleton

skeleton phenotype ( J:146078 )

N • unlike mice with conditional deletion in the gut, mice with conditional expression in osteoblasts have no significant increase in bone mass or osteoblast proliferation

Genotype
MGI:3837406

cn46

• Allelic Composition: Lrp5^{tm3(Lrp5*)Kry}/Lrp5^{tm3(Lrp5*)Kry}; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:146078 )

N • unlike mice with conditional expression in the gut, mice with conditional expression in osteoblasts have normal circulating serotonin levels

skeleton

skeleton phenotype ( J:146078 )

N • unlike mice with conditional expression in the gut, mice with conditional expression in osteoblasts have normal bone mass and bone formation

Genotype
MGI:3837402

cn47

• Allelic Composition: Lrp5^tm2Kry/Lrp5^tm2Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:146078 )

N • unlike in null mice, circulating serotonin levels are similar to controls

skeleton

skeleton phenotype ( J:146078 )

N • unlike in null mice, bone mass and osteoblast proliferation are normal

vision/eye

vision/eye phenotype ( J:146078 )

N • unlike in null mice, persistence of hyaloid vessels is not seen

Genotype
MGI:3837366

cn48

• Allelic Composition: Adrb2^tm1Kry/Adrb2^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

homeostasis/metabolism

abnormal insulin secretion ( J:145998 )

• mice treated intracerebroventricularly with leptin fail to exhibit a decrease in glucose-stimulated insulin secretion as in wild-type mice

decreased circulating glucose level ( J:145998 )

• mice exhibit postprandial low blood glucose levels compared to in wild-type mice

increased circulating insulin level ( J:145998 )

• mice exhibit elevated serum insulin levels compared to in wild-type mice that could not be increased by treatment with propranolol as in wild-type mice

• mice treated intracerebroventricularly with leptin fail to exhibit a decrease in glucose-stimulated circulating insulin levels as in wild-type mice

• however, insulin tolerance is normal

endocrine/exocrine glands

abnormal insulin secretion ( J:145998 )

• mice treated intracerebroventricularly with leptin fail to exhibit a decrease in glucose-stimulated insulin secretion as in wild-type mice

Genotype
MGI:3763086

cn49

• Allelic Composition: Ptprv^tm1Kry/Ptprv^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

mortality/aging

postnatal lethality, incomplete penetrance ( J:126780 )

• up to 15% of mice die prior to weaning when born to heterozygous mothers and up to 35% die prior to weaning when born to homozygous mothers

homeostasis/metabolism

increased circulating testosterone level ( J:170888 )

decreased circulating free fatty acids level ( J:126780 )

• following an overnight fast, serum levels of free fatty acids are not increased as they are in wild-type mice

decreased circulating triglyceride level ( J:126780 )

increased energy expenditure ( J:126780 )

• energy expenditure is higher than in wild-type mice

• however, food intake is not increased

abnormal glucose homeostasis ( J:126780 )

• insulin-stimulated glucose uptake in muscle, brown and white fat, and liver is increased compared to in wild-type mice

increased insulin secretion ( J:126780 )

decreased circulating glucose level ( J:126780 )

• blood glucose level at birth prior to milk ingestion is reduced 3-fold or more compared to in wild-type mice

hypoglycemia ( J:126780 )

• adult mice have low blood glucose levels compared to wild-type mice

increased circulating insulin level ( J:126780 )

improved glucose tolerance ( J:126780 )

increased insulin sensitivity ( J:126780 )

increased circulating adiponectin level ( J:126780 )

• serum adiponectin levels are increased by 2-fold compared to in wild-type mice

adipose tissue

increased fat cell size ( J:126780 )

• although fewer adipocytes are present (37+/-5.1x10³ adipocytes compared to 93.2+/-10.7x10³ adipocytes in wild-type mice), adipocytes are larger than in wild-type mice

decreased gonadal fat pad weight ( J:126780 )

• mice have lighter gonadal fat pads compared to wild-type mice

• decreased fat is restricted to visceral fat

increased adipocyte glucose uptake ( J:126780 )

• white adipose glucose uptake, 31.7+/-8.2 nmol/g/min compared to 16.7+/-2.7 nmol/g/min in wild-type mice; brown adipose tissue, 3330+/-263 nmol/g/min compared to 2022+/-205 nmol/g/min in wild-type mice

endocrine/exocrine glands

increased pancreatic beta cell proliferation ( J:126780 )

• beta cell proliferation is increased 60% to 300% in 5 day old and 1 month old mice with no increase in apoptosis

abnormal pancreatic islet morphology ( J:126780 )

• mice exhibit an increase in pancreas insulin content, the number of islet cells, the size of islet cells and the mass of beta cells

increased pancreatic beta cell mass ( J:126780 )

• beta cell mass is increased

increased pancreatic islet number ( J:126780 )

pancreatic islet hyperplasia ( J:126780 )

increased seminal vesicle weight ( J:170888 )

♂

increased insulin secretion ( J:126780 )

muscle

abnormal muscle fiber mitochondrial morphology ( J:126780 )

• mitochondrial area in muscle cells is increased compared to in wild-type cells

increased muscle cell glucose uptake ( J:126780 )

• insulin-stimulated glucose uptake in muscle is increased compared to in wild-type mice

• 358+/-65 nmol/g/min compared to 22+/-29 nmol/g/min in wild-type mice

cellular

increased adipocyte glucose uptake ( J:126780 )

• white adipose glucose uptake, 31.7+/-8.2 nmol/g/min compared to 16.7+/-2.7 nmol/g/min in wild-type mice; brown adipose tissue, 3330+/-263 nmol/g/min compared to 2022+/-205 nmol/g/min in wild-type mice

abnormal muscle fiber mitochondrial morphology ( J:126780 )

• mitochondrial area in muscle cells is increased compared to in wild-type cells

increased pancreatic beta cell proliferation ( J:126780 )

• beta cell proliferation is increased 60% to 300% in 5 day old and 1 month old mice with no increase in apoptosis

increased muscle cell glucose uptake ( J:126780 )

• insulin-stimulated glucose uptake in muscle is increased compared to in wild-type mice

• 358+/-65 nmol/g/min compared to 22+/-29 nmol/g/min in wild-type mice

growth/size/body

growth/size/body region phenotype ( J:126780 )

N • despite an increase in mitochondrial area muscle mass over body mass ratio is normal

skeleton

skeleton phenotype ( J:126780 )

N • no skeletal abnormalities are detected in newborn and 2 month-old mice

reproductive system

increased seminal vesicle weight ( J:170888 )

♂

increased sperm number ( J:170888 )

♂ • sperm count is increased compared to in wild-type mice

increased epididymis weight ( J:170888 )

♂

Genotype
MGI:3837410

cn50

• Allelic Composition: Htr2b^tm1Kry/Htr2b^tm1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

skeleton

skeleton phenotype ( J:146078 )

N • despite loss of expression in osteoblasts, no skeletal abnormalities are detected at 1 or 3 months of age

Genotype
MGI:4949144

cn51

• Allelic Composition: Bglap/Bglap2^tm3.1Kry/Bglap/Bglap2^tm3.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

reproductive system

oligozoospermia ( J:170888 )

♂ • at 12 weeks

decreased seminal vesicle weight ( J:170888 )

♂ • at 12 weeks

small testis ( J:170888 )

♂ • at 12 weeks

decreased testis weight ( J:170888 )

♂ • at 12 weeks

decreased epididymis weight ( J:170888 )

♂ • at 12 weeks

homeostasis/metabolism

decreased circulating testosterone level ( J:170888 )

• at 12 weeks

endocrine/exocrine glands

decreased seminal vesicle weight ( J:170888 )

♂ • at 12 weeks

small testis ( J:170888 )

♂ • at 12 weeks

decreased testis weight ( J:170888 )

♂ • at 12 weeks

cellular

oligozoospermia ( J:170888 )

♂ • at 12 weeks

Genotype
MGI:4949147

cn52

• Allelic Composition: Bglap/Bglap2^tm3.1Kry/Bglap/Bglap2^tm3.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB

reproductive system

oligozoospermia ( J:170888 )

♂ • at 12 weeks

decreased seminal vesicle weight ( J:170888 )

♂ • at 12 weeks

small testis ( J:170888 )

♂ • at 12 weeks

decreased testis weight ( J:170888 )

♂ • at 12 weeks

decreased epididymis weight ( J:170888 )

♂ • at 12 weeks

homeostasis/metabolism

decreased circulating testosterone level ( J:170888 )

• at 12 weeks

endocrine/exocrine glands

decreased seminal vesicle weight ( J:170888 )

♂ • at 12 weeks

small testis ( J:170888 )

♂ • at 12 weeks

decreased testis weight ( J:170888 )

♂ • at 12 weeks

cellular

oligozoospermia ( J:170888 )

♂ • at 12 weeks

Genotype
MGI:5689562

cn53

• Allelic Composition: Runx2^tm1Mjo/Runx2⁺; Runx3^tm3Yg/Runx3^tm3Yg; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB/N

growth/size/body

decreased body size ( J:224290 )

• dwarfism

decreased body height ( J:224290 )

• short stature

Genotype
MGI:5689556

cn54

• Allelic Composition: Runx3^tm3Yg/Runx3^tm3Yg; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB/N

growth/size/body

decreased body mass index ( J:224290 )

• 20-50% lower body mass

decreased body size ( J:224290 )

• dwarfism

decreased body weight ( J:224290 )

decreased body height ( J:224290 )

• short stature that persists throughout life

limbs/digits/tail

decreased diameter of femur ( J:224290 )

• 21.7% lower bone thickness of 23 day old femurs

decreased femoral compact bone area ( J:224290 )

• 25% smaller cortical area of 23 day old femurs

skeleton

skeleton phenotype ( J:243559 )

• do not display scoliosis at 3 months of age

decreased diameter of femur ( J:224290 )

• 21.7% lower bone thickness of 23 day old femurs

decreased femoral compact bone area ( J:224290 )

• 25% smaller cortical area of 23 day old femurs

decreased bone mineral content ( J:224290 )

• 27.1% reduction in bone mineral content in 23 day old femurs

Genotype
MGI:6198735

cn55

• Allelic Composition: Ggcx^tm1.1Kry/Ggcx^tm1.1Kry; Tg(Col1a1-cre)1Kry/0
• Genetic Background: involves: FVB/N

reproductive system

reproductive system phenotype ( J:264734 )

N • mice do not exhibit hypergonadism with normal sperm count, testis weight, epididymis weight, and seminal vesicle weight

homeostasis/metabolism

decreased susceptibility to diet-induced obesity ( J:264734 )

• when fed a high-fat diet

hypoglycemia ( J:264734 )

• in fasted mice fed a high-fat diet

abnormal circulating osteocalcin level ( J:264734 )

• increased levels of GLU-OCN 3 to 4 times

• however, total and GLA-OCN levels are normal

increased carbon dioxide production ( J:264734 )

increased oxygen consumption ( J:264734 )

improved glucose tolerance ( J:264734 )

• in female and male mice when fed a high-fat diet or a normal diet

increased insulin sensitivity ( J:264734 )

• in female and male mice when fed a high-fat diet or a normal diet

• however, hyperinsulinemia when fed a high-fat diet is normal

growth/size/body

decreased susceptibility to diet-induced obesity ( J:264734 )

• when fed a high-fat diet

thin body ( J:264734 )

adipose tissue

decreased epididymal fat pad weight ( J:264734 )